• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Exelixis and Ipsen to seek approval for Cabometyx in prostate cancer

cafead

Administrator
Staff member
  • cafead   Aug 21, 2023 at 10:02: AM
via The Phase III trial for the Cabometyx and Tecentriq combination treatment met progression-free survival endpoint in metastatic prostate cancer.

article source
 

<